LSTM Home > LSTM Research > LSTM Online Archive

Current drug development portfolio for antimalarial therapies

Biagini, Giancarlo ORCID: https://orcid.org/0000-0001-6356-6595, O'Neill, P. M., Bray, Patrick and Ward, Stephen ORCID: https://orcid.org/0000-0003-2331-3192 (2005) 'Current drug development portfolio for antimalarial therapies'. Current Opinion in Pharmacology, Vol 5, Issue 5, pp. 473-478.

Full text not available from this repository.

Abstract

In response to the emergence of parasite drug resistance to currently deployed antimalarials, the scientific community, in partnership with the pharmaceutical industry and public organizations, has fashioned an antimalarial drug development portfolio for the sustained development and registration of safe, effective and cheap antimalarial medicines. The management of this portfolio is being driven by MMV (Medicines for Malaria Venture), with a number of projects recently reaching the clinical end of this drug development pipeline.

Item Type: Article
Additional Information: This review comes from a themed issue on Anti–infectives Edited by Alisdair MacGowan and David Payne.
Subjects: QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 256 Antimalarials
QW Microbiology and Immunology > QW 45 Microbial drug resistance. General or not elsewhere classified.
WC Communicable Diseases > Tropical and Parasitic Diseases > WC 770 Therapy
Faculty: Department: Groups (2002 - 2012) > Molecular & Biochemical Parasitology Group
Digital Object Identifer (DOI): https://doi.org/10.1016/j.coph.2005.05.004
Depositing User: Ms Julia Martin
Date Deposited: 17 Aug 2011 11:14
Last Modified: 06 Feb 2018 13:02
URI: http://archive.lstmed.ac.uk/id/eprint/1876

Statistics

View details

Actions (login required)

Edit Item Edit Item